Covalent conjugation of poly(ethylene glycol) to proteins and peptides: strategies and methods
- PMID: 21674328
- DOI: 10.1007/978-1-61779-151-2_8
Covalent conjugation of poly(ethylene glycol) to proteins and peptides: strategies and methods
Abstract
PEGylation, the covalent linking of PEG chains, has become the leading drug delivery approach for proteins. This technique initiated its first steps almost 40 years ago, and since then, a variety of methods and strategies for protein-polymer coupling have been devised. PEGylation can give a number of relevant advantages to the conjugated protein, such as an important in vivo half-life prolongation, a reduction or an abolishment of immunogenicity, and a reduction of aggregation. Furthermore, the technique has demonstrated a great degree of versatility and efficacy--not only PEG-protein conjugates have reached the commercial marketplace (with nine types of derivatives), but a PEG-aptamer and PEGylated liposomes are now also available. Most of this success is due to the development of several PEGylation strategies and to the large selection of PEGylating agents presently at hand for researchers. Nevertheless, this technique still requires a certain level of familiarity and knowledge in order to achieve a positive outcome for a PEGylation project. To draw general guidelines for conducting PEGylation studies is not always easy or even possible because such experiments often require case-by-case optimization. On the other hand, several common methods can be used as starting examples for the development of tailor-made coupling conditions. Therefore, this chapter aims to provide a basic introduction to a wide range of PEGylation procedures for those researchers who may not be familiar with this field.
Similar articles
-
The impact of PEGylation on biological therapies.BioDrugs. 2008;22(5):315-29. doi: 10.2165/00063030-200822050-00004. BioDrugs. 2008. PMID: 18778113 Review.
-
Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.Bioconjug Chem. 2007 Jan-Feb;18(1):61-76. doi: 10.1021/bc0601471. Bioconjug Chem. 2007. PMID: 17226958
-
Protein-polymer conjugation-moving beyond PEGylation.Curr Opin Chem Biol. 2015 Oct;28:181-93. doi: 10.1016/j.cbpa.2015.08.009. Epub 2015 Sep 7. Curr Opin Chem Biol. 2015. PMID: 26356631 Free PMC article. Review.
-
PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques.Int J Hematol. 1998 Jul;68(1):1-18. doi: 10.1016/s0925-5710(98)00039-5. Int J Hematol. 1998. PMID: 9713164 Review.
-
PEGylation, successful approach to drug delivery.Drug Discov Today. 2005 Nov 1;10(21):1451-8. doi: 10.1016/S1359-6446(05)03575-0. Drug Discov Today. 2005. PMID: 16243265 Review.
Cited by
-
Layered PEGDA hydrogel for islet of Langerhans encapsulation and improvement of vascularization.J Mater Sci Mater Med. 2017 Nov 18;28(12):195. doi: 10.1007/s10856-017-6004-6. J Mater Sci Mater Med. 2017. PMID: 29151130 Free PMC article.
-
N-Monosubstituted Methoxy-oligo(ethylene glycol) Carbamate Ester Prodrugs of Resveratrol.Molecules. 2015 Sep 3;20(9):16085-102. doi: 10.3390/molecules200916085. Molecules. 2015. PMID: 26404221 Free PMC article.
-
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.Antibodies (Basel). 2019 Jan 1;8(1):3. doi: 10.3390/antib8010003. Antibodies (Basel). 2019. PMID: 31544809 Free PMC article. Review.
-
Factors Affecting the Pharmacology of Antibody-Drug Conjugates.Antibodies (Basel). 2018 Feb 7;7(1):10. doi: 10.3390/antib7010010. Antibodies (Basel). 2018. PMID: 31544862 Free PMC article. Review.
-
A Facile Strategy for the High Yielding, Quantitative Conversion of Polyglycol End-Groups to Amines.Polymers (Basel). 2021 Apr 26;13(9):1403. doi: 10.3390/polym13091403. Polymers (Basel). 2021. PMID: 33926044 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources